Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-MACS: Adrenalectomy vs Semaglutide in Mild Autonomous Cortisol Secretion
NCT07361874Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2026
- Primary completion
- May 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of semaglutide in Autonomous Cortisol Secretion (ACS) (3 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Change in Insulin Sensitivity (M-value) at 26 weeks. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
Autonomous Cortisol Secretion (ACS)
Beyond the preview
Go deeper on NCT07361874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361874.